Japanese pharmaceutical giant Takeda has announced plans to invest $30 billion in the United States over the next five years, a strategic move aimed at bolstering its manufacturing capabilities and accelerating research and development. The commitment comes as global pharmaceutical companies ramp up their U.S. investments amid potential tariffs on drugs and medical products introduced by the Trump administration.
“We currently plan to invest about $30 billion in the next five years in the U.S.,” said Takeda CEO Christophe Weber during an earnings call. “This is to make sure that our manufacturing sites are upgraded to be as efficient as possible.” Weber emphasized that the investment will also focus on advancing the company’s research and development efforts, ensuring Takeda maintains its competitive edge in the rapidly evolving pharmaceutical industry.
Takeda currently operates seven manufacturing facilities across the United States, including major plants in Minnesota and California. These facilities produce a range of products for the U.S. market, including Entyvio, a leading treatment for ulcerative colitis and Crohn’s disease, as well as plasma-derived products critical for various medical conditions. The planned investment will enhance these sites, modernizing their operations and supporting the development of next-generation therapies.
The $30 billion investment positions Takeda among several major pharmaceutical companies significantly increasing their U.S. presence. Swiss companies Novartis and Roche have also announced plans to invest $23 billion and $50 billion, respectively, in the U.S. over the next five years. American pharmaceutical leaders are following suit, with Eli Lilly committing $27 billion and Johnson & Johnson planning to invest at least $55 billion over four years.
The wave of investments is driven in part by U.S. policy shifts, including potential tariffs on imported pharmaceuticals, which have prompted companies to localize production and strengthen their U.S. supply chains. For Takeda, the commitment to U.S. manufacturing and research is a strategic move to mitigate tariff risks while maintaining its position as a leading player in the global pharmaceutical market.
As Takeda continues to enhance its U.S. operations, the company is expected to drive innovation, create high-quality jobs, and contribute to the resilience of the American healthcare supply chain.
